{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:48:32Z","timestamp":1791895712356,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1124\/molpharm.124.000947","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T10:00:18Z","timestamp":1729159218000},"page":"240-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors"],"prefix":"10.1016","volume":"106","author":[{"given":"Ivone","family":"Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achla","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyssa B.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd D.","family":"Fricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-2874","authenticated-orcid":false,"given":"Lakshmi A.","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.124.000947_bib1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1021\/ml5005365","article-title":"Allosteric modulators: an emerging concept in drug discovery","volume":"6","author":"Abdel-Magid","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/molpharm.124.000947_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121803","article-title":"Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine","volume":"326","author":"Adzic","year":"2023","journal-title":"Life Sci"},{"key":"10.1124\/molpharm.124.000947_bib3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1124\/molpharm.124.000947_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265928","article-title":"Antidepressants and health-related quality of life (HRQoL) for patients with depression: Analysis of the medical expenditure panel survey from the United States","volume":"17","author":"Almohammed","year":"2022","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.124.000947_bib5","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression","volume":"388","author":"Anand","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1124\/molpharm.124.000947_bib6","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17f11681","article-title":"Ketamine for Depression, 3: Does Chirality Matter?","volume":"78","author":"Andrade","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/ACO.0000000000000916","article-title":"Ketamine: a versatile tool for anesthesia and analgesia","volume":"33","author":"Barrett","year":"2020","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1124\/molpharm.124.000947_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib9","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/ijnp\/pyx079","article-title":"Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine","volume":"21","author":"Browne","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/molpharm.124.000947_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/HRP.0000000000000242","article-title":"Novel Targets to Treat Depression: Opioid-Based Therapeutics","volume":"28","author":"Browne","year":"2020","journal-title":"Harv Rev Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2019.04.009","article-title":"Targeting opioid dysregulation in depression for the development of novel therapeutics","volume":"201","author":"Browne","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1124\/molpharm.124.000947_bib13","doi-asserted-by":"crossref","first-page":"10830","DOI":"10.1073\/pnas.1300393110","article-title":"Discovery of positive allosteric modulators and silent allosteric modulators of the mu-opioid receptor","volume":"110","author":"Burford","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.124.000947_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0014-2999(83)90181-4","article-title":"Inhibition of enkephalin metabolism by, and antinociceptive activity of, bestatin, an aminopeptidase inhibitor","volume":"86","author":"Chaillet","year":"1983","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib15","doi-asserted-by":"crossref","first-page":"16198","DOI":"10.1074\/jbc.RA119.008685","article-title":"Ligand-dependent spatiotemporal signaling profiles of the mu-opioid receptor are controlled by distinct protein-interaction networks","volume":"294","author":"Civciristov","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.124.000947_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/wps.20229","article-title":"What has serotonin to do with depression?","volume":"14","author":"Cowen","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib17","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1074\/jbc.271.8.4073","article-title":"Thr353, located within the COOH-terminal tail of the delta opiate receptor, is involved in receptor down-regulation","volume":"271","author":"Cvejic","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.124.000947_bib18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.bcp.2018.07.014","article-title":"Impact of allosteric modulation: Exploring the binding kinetics of glutamate and other orthosteric ligands of the metabotropic glutamate receptor 2","volume":"155","author":"Doornbos","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib19","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/j.1460-9568.2010.07466.x","article-title":"Delta opioid receptor-mediated analgesia is not altered in preprotachykinin A knockout mice","volume":"32","author":"Dubois","year":"2010","journal-title":"Eur J Neurosci"},{"key":"10.1124\/molpharm.124.000947_bib20","first-page":"33","article-title":"Interactions of ketamine, naloxone and morphine in the rat","volume":"39","author":"Fidecka","year":"1987","journal-title":"Pol J Pharmacol Pharm"},{"key":"10.1124\/molpharm.124.000947_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00000542-198204000-00011","article-title":"Opiate receptor mediation of ketamine analgesia","volume":"56","author":"Finck","year":"1982","journal-title":"Anesthesiology"},{"key":"10.1124\/molpharm.124.000947_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1124\/mol.120.119388","article-title":"Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions","volume":"98","author":"Fricker","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.30","article-title":"The atypical antidepressant and neurorestorative agent tianeptine is a mu-opioid receptor agonist","volume":"4","author":"Gassaway","year":"2014","journal-title":"Transl Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib24","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.pain.2010.12.031","article-title":"Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia","volume":"152","author":"Gaveriaux-Ruff","year":"2011","journal-title":"Pain"},{"key":"10.1124\/molpharm.124.000947_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad0694","article-title":"Identification of GPR83 as the receptor for the neuroendocrine peptide PEN","volume":"9","author":"Gomes","year":"2016","journal-title":"Sci Signal"},{"key":"10.1124\/molpharm.124.000947_bib26","doi-asserted-by":"crossref","first-page":"11820","DOI":"10.1073\/pnas.2000712117","article-title":"Biased signaling by endogenous opioid peptides","volume":"117","author":"Gomes","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.124.000947_bib27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","article-title":"Potentiation of mu-opioid receptor-mediated signaling by ketamine","volume":"119","author":"Gupta","year":"2011","journal-title":"J Neurochem"},{"key":"10.1124\/molpharm.124.000947_bib28","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1073\/pnas.1521825113","article-title":"Collybolide is a novel biased agonist of kappa-opioid receptors with potent antipruritic activity","volume":"113","author":"Gupta","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.124.000947_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114892","article-title":"Mechanisms of ketamine and its metabolites as antidepressants","volume":"197","author":"Hess","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00000542-199901000-00023","article-title":"Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells","volume":"90","author":"Hirota","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1124\/molpharm.124.000947_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s005400050035","article-title":"Interaction of ketamine with mu2 opioid receptors in SH-SY5Y human neuroblastoma cells","volume":"13","author":"Hirota","year":"1999","journal-title":"J Anesth"},{"key":"10.1124\/molpharm.124.000947_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aar4309","article-title":"G protein signaling-biased agonism at the kappa-opioid receptor is maintained in striatal neurons","volume":"11","author":"Ho","year":"2018","journal-title":"Sci Signal"},{"key":"10.1124\/molpharm.124.000947_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0773.1995.tb01041.x","article-title":"Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors","volume":"77","author":"Hustveit","year":"1995","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/molpharm.124.000947_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/09540261.2020.1854194","article-title":"Ketamine for depression","volume":"33","author":"Jelen","year":"2021","journal-title":"Int Rev Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104800","article-title":"The opioid system in depression","volume":"140","author":"Jelen","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1124\/molpharm.124.000947_bib36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","article-title":"Ketamine: A tale of two enantiomers","volume":"35","author":"Jelen","year":"2021","journal-title":"J Psychopharmacol"},{"key":"10.1124\/molpharm.124.000947_bib37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41398-024-02796-0","article-title":"The endogenous opioid system in the medial prefrontal cortex mediates ketamine\u2019s antidepressant-like actions","volume":"14","author":"Jiang","year":"2024","journal-title":"Transl Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/21441","article-title":"G-protein-coupled receptor heterodimerization modulates receptor function","volume":"399","author":"Jordan","year":"1999","journal-title":"Nature"},{"key":"10.1124\/molpharm.124.000947_bib39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1021\/acschemneuro.0c00741","article-title":"Ketamine Metabolite (2R,6R)-Hydroxynorketamine Interacts with mu and kappa Opioid Receptors","volume":"12","author":"Joseph","year":"2021","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/molpharm.124.000947_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2000017118","article-title":"Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects","volume":"118","author":"Kandasamy","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.124.000947_bib41","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.124.000947_bib42","first-page":"33","article-title":"Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress","volume":"34","author":"Kritzer","year":"2022","journal-title":"Ann Clin Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1476-5381.1981.tb10440.x","article-title":"Opiate-like analgesic activity in general anaesthetics","volume":"73","author":"Lawrence","year":"1981","journal-title":"Br J Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41386-023-01652-x","article-title":"Exploring the role of mu opioid receptors in the therapeutic potential and abuse liability of (S)-ketamine","volume":"49","author":"Levinstein","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.124.000947_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.117.109561","article-title":"Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors","volume":"93","author":"Livingston","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib46","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1111\/bph.13823","article-title":"Allostery at opioid receptors: modulation with small molecule ligands","volume":"175","author":"Livingston","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib47","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41586-023-06624-1","article-title":"Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb","volume":"622","author":"Ma","year":"2023","journal-title":"Nature"},{"key":"10.1124\/molpharm.124.000947_bib48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pharmthera.2009.02.010","article-title":"Ketamine and the next generation of antidepressants with a rapid onset of action","volume":"123","author":"Machado-Vieira","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1124\/molpharm.124.000947_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1124\/molpharm.122.000487","article-title":"GPR83 engages endogenous peptides from two distinct precursors to elicit differential signaling","volume":"102","author":"Mack","year":"2022","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0006-8993(95)00928-J","article-title":"The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores","volume":"700","author":"Mansour","year":"1995","journal-title":"Brain Res"},{"key":"10.1124\/molpharm.124.000947_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2019.02.008","article-title":"Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine\u2019s Antidepressant Activity","volume":"85","author":"Marton","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib52","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/j.1471-4159.2008.05745.x","article-title":"Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways","volume":"107","author":"McLennan","year":"2008","journal-title":"J Neurochem"},{"key":"10.1124\/molpharm.124.000947_bib53","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/00000542-199906000-00007","article-title":"The effect of naloxone on ketamine-induced effects on hyperalgesia and ketamine-induced side effects in humans","volume":"90","author":"Mikkelsen","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1124\/molpharm.124.000947_bib54","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12094","article-title":"Ketamine for chronic pain: risks and benefits","volume":"77","author":"Niesters","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib55","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41589-020-0535-8","article-title":"TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome","volume":"16","author":"Olsen","year":"2020","journal-title":"Nat Chem Biol"},{"key":"10.1124\/molpharm.124.000947_bib56","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1213\/ANE.0000000000004185","article-title":"Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"129","author":"Orhurhu","year":"2019","journal-title":"Anesth Analg"},{"key":"10.1124\/molpharm.124.000947_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","article-title":"Central antinociception induced by ketamine is mediated by endogenous opioids and mu- and delta-opioid receptors","volume":"1562","author":"Pacheco","year":"2014","journal-title":"Brain Res"},{"key":"10.1124\/molpharm.124.000947_bib58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euroneuro.2021.01.005","article-title":"Comparative effects of (S)-ketamine and racemic (R\/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers","volume":"44","author":"Passie","year":"2021","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1124\/molpharm.124.000947_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172808","article-title":"Peripheral antinociception induced by ketamine is mediated by the endogenous opioid system","volume":"865","author":"Petrocchi","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib60","series-title":"This Is Your Mind on Plants","author":"Pollan","year":"2021"},{"key":"10.1124\/molpharm.124.000947_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108673","article-title":"A promising chemical series of positive allosteric modulators of the mu-opioid receptor that enhance the antinociceptive efficacy of opioids but not their adverse effects","volume":"195","author":"Pryce","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.124.000947_bib62","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1124\/pr.111.004598","article-title":"Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance","volume":"63","author":"Raehal","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1124\/molpharm.124.000947_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106961","article-title":"IUPHAR themed review: Opioid efficacy, bias, and selectivity","volume":"197","author":"Ramos-Gonzalez","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1124\/molpharm.124.000947_bib64","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/npp.2017.60","article-title":"The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor","volume":"42","author":"Samuels","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.124.000947_bib65","article-title":"Ketamine Metabolites Enantioselectively Decrease Intracellular D-Serine Concentrations in PC-12 Cells","volume":"11","author":"Singh","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.124.000947_bib66","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tips.2020.12.005","article-title":"Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery","volume":"42","author":"Slosky","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/molpharm.124.000947_bib67","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0024-3205(80)90285-4","article-title":"The interaction of ketamine with the opiate receptor","volume":"26","author":"Smith","year":"1980","journal-title":"Life Sci"},{"key":"10.1124\/molpharm.124.000947_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2018.04.021","article-title":"A Genetically Encoded Biosensor Reveals Location Bias of Opioid Drug Action","volume":"98","author":"Stoeber","year":"2018","journal-title":"Neuron"},{"key":"10.1124\/molpharm.124.000947_bib69","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1211\/0022357011775622","article-title":"Antinociceptive effect of U-50488H, a kappa-opioid agonist, in streptozotocin-induced diabetic mice","volume":"53","author":"Suzuki","year":"2001","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib70","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bcp.2016.05.014","article-title":"Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor","volume":"113","author":"Thompson","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib71","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0169-328X(00)00002-4","article-title":"Opioid receptor endocytosis and activation of MAP kinase pathway","volume":"76","author":"Trapaidze","year":"2000","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1124\/molpharm.124.000947_bib72","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1124\/mol.111.074872","article-title":"Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects","volume":"81","author":"Valant","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0014-2999(00)00769-X","article-title":"kappa-opioid receptor-mediated analgesia: hotplate temperature and sex differences","volume":"408","author":"van Haaren","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib74","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0024-3205(82)90079-0","article-title":"Lack of antagonism by naloxone of the analgesic and locomotor stimulant actions of ketamine","volume":"31","author":"Wiley","year":"1982","journal-title":"Life Sci"},{"key":"10.1124\/molpharm.124.000947_bib75","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","article-title":"Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism","volume":"24","author":"Williams","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib76","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib77","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00213-022-06118-4","article-title":"Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors","volume":"239","author":"Wulf","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.124.000947_bib78","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1038\/s41467-023-42780-8","article-title":"Enhanced TARP-gamma8-PSD-95 coupling in excitatory neurons contributes to the rapid antidepressant-like action of ketamine in male mice","volume":"14","author":"Xue","year":"2023","journal-title":"Nat Commun"},{"key":"10.1124\/molpharm.124.000947_bib79","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/jpet.122.001278","article-title":"Antinociceptive and Analgesic Effects of (2R,6R)-Hydroxynorketamine","volume":"382","author":"Yost","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.124.000947_bib80","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1124\/molpharm.124.000947_bib81","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1124\/molpharm.124.000947_bib82","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/molpharm.124.000947_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173228","article-title":"Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice","volume":"208","author":"Zhang","year":"2021","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/molpharm.124.000947_bib84","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1073\/pnas.0802253105","article-title":"Agonist-selective signaling is determined by the receptor location within the membrane domains","volume":"105","author":"Zheng","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.124.000947_bib85","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1124\/mol.107.039842","article-title":"Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation","volume":"73","author":"Zheng","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1228895","article-title":"Recent advances in the study of anesthesia-and analgesia-related mechanisms of S-ketamine","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1124\/molpharm.124.000947_bib87","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA Receptors and Beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J Neurosci"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24018273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24018273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.124.000947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T14:54:06Z","timestamp":1739285646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24018273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0026895X24018273"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.124.000947","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.124.000947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}